RPBS
For a veteran in outback Queensland newly diagnosed with a terminal illness, "find a specialist and attend in person first" is not a neutral administrative requirement. It is a genuine barrier to care, arriving at the worst possible time.
study
The study was supported by philanthropic funding to the HealthPartners Cancer Research Centre, with cannabis products provided by Vireo Health (GreenGoods, Minnesota).
Legalise Cannabis Australia
Recruitment of adults with medicinal cannabis prescriptions has now concluded.
Trump
Schedule III classification would recognise cannabis as having accepted medical use and lower abuse potential than Schedule I or II substances.
medical cannabis
The 22% reduction in opioid use may seem modest, but researchers emphasise this aligns with current clinical recommendations for gradual opioid tapering over extended periods rather than rapid cessation.
hemp
The most alarming finding from the trials is the catastrophic variability in imported seed quality.
hyperspectral
The implications for Australia's emerging cannabis industry are substantial.
The implications for Australia's emerging cannabis industry are substantial.
Sativex represents the first plant-derived cannabinoid medicine approved by a medicines regulator, a distinction that underscores its pioneering role in legitimising cannabis-based therapeutics.
The debt forgiveness of $54.7 million represents an 81% reduction in the company's debt and will increase Cann Group's net assets by approximately $60 million.
The Reviewing the Safety and Regulatory Oversight of Unapproved Medicinal Cannabis Products consultation commenced on 11 August 2025 and will close on 7 October.
You know you want to..
Sativex represents the first plant-derived cannabinoid medicine approved by a medicines regulator, a distinction that underscores its pioneering role in legitimising cannabis-based therapeutics.
The industry's 38 tonnes of unsold inventory isn't just an economic problem. It's karma.
The debt forgiveness of $54.7 million represents an 81% reduction in the company's debt and will increase Cann Group's net assets by approximately $60 million.
The contrast between Germany's success and Australia's stagnation raises a fundamental question: what structural differences enable one country to achieve rapid market transformation while another remains locked in gatekeeping and corporate control?
As health bodies call for crackdown on rogue operators, affordability crisis goes unaddressed.
The Reviewing the Safety and Regulatory Oversight of Unapproved Medicinal Cannabis Products consultation commenced on 11 August 2025 and will close on 7 October.
Ecofibre Limited was an Australian biotechnology company focused on hemp-derived products and technologies. The company listed on the ASX on March 29, 2019, through an IPO that raised $20 million at $1 per share, giving it a market capitalization of $309 million on listing¹. The business was headed by rich-lister
The prohibition creates a two-tiered system where access depends on wealth. Canadian patients can grow unlimited plants based on prescription. Low-income patients aren't excluded due to cost barriers.
The consultation does not address home cultivation as a potential solution to affordability concerns, despite this approach being adopted in countries like Canada and several European nations.
A groundbreaking study has provided the first definitive proof that legal medical cannabis can be a deadly source of infection for vulnerable patients.
The research suggests that cannabis cultivators face a trade-off when growing purple varieties.
Australia's approach to road safety offers valuable lessons for drug policy.